继发性甲状旁腺功能亢进

Eknoyan G, Levin A, Levin NW; National Kidney Foundation. KDOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1-S201.

• 全文
• 摘要

Ahmad R, Hammond JM. Primary, secondary, and tertiary hyperparathyroidism. Otolaryngol Clin North Am. 2004;37:701-713.

• 摘要

Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76(Suppl 113):S1-S130.

• 全文
• 摘要

Cheng J, Zhang W, Zhang X, et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:391-400.

• 摘要

Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27:3270-3278.

• 全文
• 摘要

Chertow GM, Block GA, Correa-Rotter R, et al; EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482-2494.

• 全文
• 摘要

Ballinger AE, Palmer SC, Nistor I, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014;(12):CD006254.

• 全文
• 摘要

1.  Moe S, Drüeke T, Cunningham J, et al; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945-1953.

• 全文
• 摘要

2.  Ginde AA, Liu MC, Camargo CA Jr. Demographic differences and trends of vitamin D insufficiency in the U.S. population, 1988-2004. Arch Intern Med. 2009;169:626-632.

• 摘要

3.  Holick MF. The vitamin D epidemic and its health consequences. J Nutr. 2005;135:2739S-2748S.

• 全文
• 摘要

4.  National Institutes of Health, Office of Dietary Supplements. Vitamin D: factsheet for health professionals. February 2016. http://ods.od.nih.gov/ (last accessed 26 September 2017).

• 全文

5.  Goldner WS, Stoner JA, Thompson J, et al. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: a comparison with non-obese controls. Obes Surg. 2008;18:145-150.

• 摘要

6.  Jean G, Lafage-Proust MH, Massy ZA, et al. Guidelines for vitamin D prescription in dialysis patients [in French]. Nephrol Ther. 2009;5:520-532.

• 摘要

7.  Martin KJ, González EA. Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat? Clin J Am Soc Nephrol. 2011;6:440-446.

• 全文
• 摘要

8.  Dhingra R, Sullivan LM, Fox CS, et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007;167:879-885.

• 全文
• 摘要

9.  de Boer IH, Rue TC, Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis. 2009;53:399-407.

• 全文
• 摘要

10.  Malluche HH, Porter DS, Pienkowski D. Evaluating bone quality in patients with chronic kidney disease. Nat Rev Nephrol. 2013;9:671-680.

• 全文
• 摘要

11.  Felsenfeld AJ, Rodríguez M, Aguilera-Tejero E. Dynamics of parathyroid hormone secretion in health and secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2007;2:1283-1305.

• 全文
• 摘要

12.  McKane WR, Khosla S, Egan KS, et al. Role of calcium intake in modulating age-related increases in parathyroid function and bone resorption. J Clin Endocrinol Metab. 1996;81:1699-1703.

• 摘要

13.  Bruyere O, Decock C, Delhez M, et al. Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study. Womens Health (Lond Engl). 2009;5:49-54.

• 摘要

14.  Trunzo JA, McHenry CR, Schulak JA, et al. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism. Surgery. 2008;144:915-918.

• 摘要

15.  Silverberg SJ. Vitamin D deficiency and primary hyperparathyroidism. J Bone Miner Res. 2007;22(suppl S2):V100-V104.

• 全文
• 摘要

16.  Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev. 2001;22:477-501.

• 摘要

17.  Holick MF, Binkley NC, Bischoff-Ferrari HA, et al; Endocrine Society. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1911-1930.

• 全文
• 摘要

18.  Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690-693. [Erratum in: Am J Clin Nutr. 2003;77:1342.]

• 全文
• 摘要

19.  Eknoyan G, Levin A, Levin NW; National Kidney Foundation. KDOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am J Kidney Dis. 2003;42(suppl 3):S1-S201.

• 全文
• 摘要

20.  National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. 2005. http://www2.kidney.org/ (last accessed 26 September 2017).

• 全文

21.  Manns B, Stevens L, Miskulin D, et al. A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States. Kidney Int. 2004;66:1239-1247.

• 全文
• 摘要

22.  Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med. 2003;349:446-456.

• 全文
• 摘要

23.  Ahmad R, Hammond JM. Primary, secondary, and tertiary hyperparathyroidism. Otolaryngol Clin North Am. 2004;37:701-713.

• 摘要

24.  Lyman D. Undiagnosed vitamin D deficiency in the hospitalized patient. Am Fam Physician. 2005;71:299-304.

• 摘要

25.  Stracke S, Keller F, Steinbach G, et al. Long-term outcome after total parathyroidectomy for the management of secondary hyperparathyroidism. Nephron Clin Pract. 2009;111:102-109.

• 摘要

26.  Redman C, Bodenner D, Stack B Jr. Role of vitamin D deficiency in continued hyperparathyroidism following parathyroidectomy. Head Neck. 2009;31:1164-1167.

• 摘要

27.  Stevens LA, Coresh J, Greene T, et al. Assessing kidney function - measured and estimated glomerular filtration rate. N Engl J Med. 2006;354:2473-2483.

• 摘要

28.  Caldarella C, Treglia G, Pontecorvi A, et al. Diagnostic performance of planar scintigraphy using 99mTc-MIBI in patients with secondary hyperparathyroidism: a meta-analysis. Ann Nucl Med. 2012;26:794-803.

• 摘要

29.  Hindié E, Ugur O, Fuster D, et al. 2009 EANM parathyroid guidelines. Eur J Nucl Med Mol Imaging. 2009;36:1201-1216.

• 全文
• 摘要

30.  Moore C, Murphy MM, Keast DR, et al. Vitamin D intake in the United States. J Am Diet Assoc. 2004;104:980-983.

• 摘要

31.  Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial. 2008;12:514-525.

• 摘要

32.  National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(suppl 1):S1-S266.

• 全文
• 摘要

33.  Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelines for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2009;76(Suppl 113):S1-S130.

• 全文
• 摘要

34.  Martin KJ, González EA. Parathyroid hormone assay: problems and opportunities. Pediatr Nephrol. 2007;22:1651-1654.

• 全文
• 摘要

35.  Isakova T, Gutiérrez OM, Wolf M. A blueprint for randomized trials targeting phosphorus metabolism in chronic kidney disease. Kidney Int. 2009;76:705-716.

• 全文
• 摘要

36.  Russo D, Miranda I, Ruocco C, et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72:1255-1261.

• 全文
• 摘要

37.  Lafage MH, Combe C, Fournier A, et al. Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int. 1992;42:1217-1225.

• 摘要

38.  Lafage-Proust MH, Combe C, Barthe N, et al. Bone mass and dynamic parathyroid function according to bone histology in nondialyzed uremic patients after long-term protein and phosphorus restriction. J Clin Endocrinol Metab. 1999;84:512-519.

• 全文
• 摘要

39.  Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease? Am J Clin Nutr. 2008;88:1511-1518.

• 全文
• 摘要

40.  Sherman RA, Mehta O. Dietary phosphorus restriction in dialysis patients: potential impact of processed meat, poultry, and fish products as protein sources. Am J Kidney Dis. 2009;54:18-23.

• 摘要

41.  Sherman RA, Mehta O. Phosphorus and potassium content of enhanced meat and poultry products: implications for patients who receive dialysis. Clin J Am Soc Nephrol. 2009;4:1370-1373.

• 全文
• 摘要

42.  Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA. 2009;301:629-635.

• 全文
• 摘要

43.  Lewis R. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management. Ann Clin Biochem. 2012;49:432-440.

• 摘要

44.  National Institute for Health and Care Excellence. Chronic kidney disease (stage 4 or 5): management of hyperphosphataemia. March 2013. http://www.nice.org.uk/ (last accessed 26 September 2017).

• 全文

45.  Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant. 2009;24:3168-3174.

• 全文
• 摘要

46.  Ortiz A, Sanchez-Niño MD. The demise of calcium-based phosphate binders. Lancet. 2013;382:1232-1234.

• 摘要

47.  Frazão JM, Braun J, Messa P, et al. Is serum phosphorus control related to parathyroid hormone control in dialysis patients with secondary hyperparathyroidism? BMC Nephrol. 2012;13:76.

• 摘要

48.  Björkman M, Sorva A, Tilvis R. Responses of parathyroid hormone to vitamin D supplementation: a systematic review of clinical trials. Arch Gerontol Geriatr. 2009;48:160-166.

• 摘要

49.  Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2009;(4):CD008175.

• 全文
• 摘要

50.  Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev. 2009;(4):CD005633.

• 全文
• 摘要

51.  Bolasco P. Treatment options of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease stages 3 and 4: an historic review. Clin Cases Miner Bone Metab. 2009;6:210-219.

• 摘要

52.  Kooienga L, Fried L, Scragg R. The effect of combined calcium and vitamin D3 supplementation on serum intact parathyroid hormone in moderate CKD. Am J Kidney Dis. 2009;53:408-416.

• 摘要

53.  Coyne DW, Goldberg S, Faber M, et al. A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD. Clin J Am Soc Nephrol. 2014;9:1620-1626.

• 全文
• 摘要

54.  Tominaga Y, Matsuoka S, Uno N. Surgical and medical treatment of secondary hyperparathyroidism in patients on continuous dialysis. World J Surg. 2009;33:2335-2342.

• 摘要

55.  Joy MS, Karagiannis PC, Peyerl FW, et al. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm. 2007;13:397-411.

• 全文
• 摘要

56.  Cheng J, Zhang W, Zhang X, et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2012;7:391-400.

• 摘要

57.  Ketteler M, Martin KJ, Wolf M, et al. Paricalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant. 2012;27:3270-3278.

• 全文
• 摘要

58.  Cruzado JM, Moreno P, Torregrosa JV, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27:2487-2494.

• 全文
• 摘要

59.  Chonchol M, Locatelli F, Abboud HE, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53:197-207.

• 摘要

60.  National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. January 2007. http://www.nice.org.uk/ (last accessed 26 September 2017).

• 全文

61.  Dong BJ. Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther. 2005;27:1725-1751.

• 摘要

62.  Elder GJ. Parathyroidectomy in the calcimimetic era. Nephrology (Carlton). 2005;10:511-515.

• 摘要

63.  Moe SM, Abdalla S, Chertow GM, et al. Effects of cinacalcet on fracture events in patients receiving hemodialysis: the EVOLVE trial. J Am Soc Nephrol. 2015;26:1466-1475.

• 全文
• 摘要

64.  Chertow GM, Block GA, Correa-Rotter R, et al; EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482-2494.

• 全文
• 摘要

65.  Ballinger AE, Palmer SC, Nistor I, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014;(12):CD006254.

• 全文
• 摘要

66.  Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327-1339.

• 摘要

67.  Henschkowski J, Bischoff-Ferrari HA, Wüthrich RP, et al. Renal function in patients treated with cinacalcet for persistent hyperparathyroidism after kidney transplantation. Kidney Blood Press Res. 2011;34:97-103.

• 摘要

68.  Floege J, Raggi P, Block GA, et al. Study design and subject baseline characteristics in the ADVANCE study: effects of cinacalcet on vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:1916-1923.

• 全文
• 摘要

69.  Frazão JM, Messa P, Mellotte GJ, et al. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol. 2011;76:233-243.

• 摘要

70.  Cohen JB, Gordon CE, Balk EM, et al. Cinacalcet for the treatment of hyperparathyroidism in kidney transplant recipients: a systematic review and meta-analysis. Transplantation. 2012;94:1041-1048.

• 摘要

71.  Zhang Q, Li M, You L, et al. Effects and safety of calcimimetics in end stage renal disease patients with secondary hyperparathyroidism: a meta-analysis. PLoS One. 2012;7:e48070.

• 全文
• 摘要

72.  Verheyen N, Pilz S, Eller K, et al. Cinacalcet hydrochloride for the treatment of hyperparathyroidism. Expert Opin Pharmacother. 2013;14:793-806.

• 摘要

73.  Rodriguez M, Ureña-Torres P, Pétavy F, et al. Calcium-mediated parathyroid hormone suppression to assess progression of secondary hyperparathyroidism during treatment among incident dialysis patients. J Clin Endocrinol Metab. 2013;98:618-625.

• 摘要

74.  Floege J, Kubo Y, Floege A, et al. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol. 2015;10:800-807.

• 全文
• 摘要

75.  Triponez F, Clark OH, Vanrenthergem Y, et al. Surgical treatment of persistent hyperparathyroidism after renal transplantation. Ann Surg. 2008;248:18-30.

• 摘要

76.  Patel HP, Chadwick DR, Harrison BJ, et al. Systematic review of intravenous methylene blue in parathyroid surgery. Br J Surg. 2012;99:1345-1351.

• 摘要

77.  Bell G, Huang S, Martin KJ, et al. A randomized, double-blind, phase 2 study evaluating the safety and efficacy of AMG 416 for the treatment of secondary hyperparathyroidism in hemodialysis patients. Curr Med Res Opin. 2015;31:943-952.

• 摘要

78.  Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.

• 全文
• 摘要

79.  Beus KS, Stack BC Jr. Calciphylaxis. Otolaryngol Clin North Am. 2004;37:941-948.

• 摘要